Sorry, can someone explain what MASH actually is? I see people mention liver disease but I thought the GLP-1 drugs were for weight loss and diabetes. How does the liver fit into this?
Great question. MASH (metabolic dysfunction-associated steatohepatitis) is basically the severe form of fatty liver disease. Here's the progression:
MASH affects an estimated 5-7% of the global adult population and is becoming the leading cause of liver transplantation. It's intimately connected to obesity and insulin resistance, which is why GLP-1-based drugs are so promising for this condition.
Until very recently, there were NO approved drugs for MASH. Resmetirom (Rezdiffra) was the first, approved in 2024, but its efficacy is modest. That's why the incretin data in MASH is generating so much excitement.
The liver angle is really underappreciated in the public conversation about GLP-1 drugs. Everyone talks about weight loss and diabetes, but MASH could end up being one of the biggest indications by market size. An estimated 15-20 million Americans have MASH, and most don't even know it.
If survodutide gets approved for MASH with those Phase 2 efficacy numbers, the commercial potential is massive. And unlike obesity, MASH has established diagnostic pathways and less insurance resistance (it's a defined liver disease, not a "lifestyle" condition).
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsImportant thread. I want to emphasize that if anyone here has been diagnosed with or suspects they have fatty liver disease, please work with a hepatologist. The drugs discussed here are not yet available for MASH outside of clinical trials.
In the meantime, weight loss through any means (lifestyle, bariatric surgery, or existing approved medications) remains the most evidence-based approach to improving MASH. Even 5-7% weight loss can meaningfully reduce liver fat and inflammation.